Inflammatory hepatitis is an uncommon cause of treatment interruption in the management of NSCLC with estimates <1% incidence of grade 3 hepatitis and 1%–3% of all grade hepatitis with the use of anti-PD-1/PD-L1 treatment in NSCLC (20, 21). This evidence concerns the gene CD274 and non-small cell lung carcinoma.